Further, several commercial vendors promote BRCA1/2 testing in patients with a history of melanoma, so it is important for patients and the healthcare system to establish whether such testing is warranted, not only because of the associated cost but also because genetic testing can be associated with significant patient anxiety. This evidence concerns the gene BRCA1 and melanoma.